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Hypoglycemic, hypolipidemic and antioxidant
eﬀects of iridoid glycosides extracted from Corni
fructus: possible involvement of the PI3K–Akt/PKB
signaling pathway†
Jiefang Kang,‡a Chen Guo, ‡a Rodolfo Thome,b Ning Yang,a Yuan Zhang,a
Xing Li *a and Xiaoyan Cao *a
Iridoid glycosides (CIG) are the major component of Corni fructus. In this work, we researched the
antioxidative, hypoglycemic and lowering blood lipids eﬀects of CIG on diabetic mice induced by a high-
fat diet (HFD) and streptozotocin (STZ). Furthermore, to investigate the molecular mechanism of action,
the phosphorylation and protein expression of phosphoinositide 3-kinase (PI3K) and its downstream
proteins, such as insulin receptor (INSR), protein kinase B (Akt/PKB) and glucose transporter 4 (GLUT4)
have been detected. The results showed that CIG signiﬁcantly improved oral glucose tolerance in
diabetic mice. Biochemical indices also revealed that CIG had a positive eﬀect on lipid metabolism and
oxidative stress. In addition, CIG can signiﬁcantly enhance the expression level of the PI3K–Akt/PKB
pathway related proteins in skeletal muscle, which is the key pathway of insulin metabolism. These
ﬁndings show that CIG can improve the hyperglycemia and hyperlipidemia of HFD–STZ-induced
diabetic mice through the PI3K–Akt/PKB signaling pathway, and CIG might be a potential medicine or
functional food for type 2 diabetes mellitus remedies.
1. Introduction
Diabetes is one of the most common chronic diseases in the
world, and its prevalence is increasing dramatically. It was
estimated that there were 425 million people with diabetes
across the world in 2017, according to the International Dia-
betes Federation (IDF) programs, and this gure is expected to
increase to 642 million by 2040.1 About 90% of these patients
with diabetes have type 2 diabetes mellitus (T2DM).2 T2DM is
a metabolic disease based on hyperglycemia characters and is
due to insulin resistance (IR) caused by a progressive insulin
secretory defect or by a lack of response of insulin receptors.3
Persistently high blood glucose levels may lead to a variety of
long-term complications, which include but are not limited to
cardiovascular and renal diseases, retinopathy, and poor blood
ow.4 Although the existing management strategies for T2DM
have achieved great results, the tolerability and obvious side
eﬀects still cannot be ignored.5–7
Natural products with fewer side eﬀects that are relatively
inexpensive to use as novel therapies to treat diabetes are the
focus of recent research.8,9 Corni fructus, the dried fruit of
Cornus oﬃcinalis Sieb. et Zucc., also known as “Shan Zhu Yu” in
Chinese, is an important crude herb used in Chinese medicine
that possesses a variety of biological activities, such as anti-
hyperglycemia,10 anti-inammation,11 anti-oxidant,12 anti-
aging,13 and liver, neural and kidney protection.14,15 There are
many chemical components in Corni fructus, including iridoid
glycosides, avonoids, organic acids, saccharides, and
tannins.16 Iridoid glycosides are a group of active substance
such as morroniside, loganin, cornuside and sweroside. Previ-
ously studies demonstrated that loganin had a protective eﬀect
against hepatic oxidative stress,17 morroniside showed eﬀective
anti-inammatory properties in AMI rats,18 sweroside could
ameliorate liver injury by decreasing oxidative damage and
inhibiting the production of proinammatory kinases,19,20 and
cornuside has been reported to possess immunomodulatory
and anti-inammatory activities.21,22 However, the underlying
mechanisms of the therapeutic potential of CIG for diabetes
have yet to be elucidated.
IR, a remarkable feature of T2DM, which was dened as
a reduction in the physiological level of insulin by cells or
tissues. is.23 Insulin signal transduction begins with the binding
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of insulin to insulin receptor (INSR) and involves the ne
regulation of phosphorylation and dephosphorylation of signal
molecules in intracellular signal transduction.24,25 Tyrosine
phosphorylation of insulin receptor substrate is induced
through the combining of insulin and insulin receptor, fol-
lowed by transduction of downstream enzymes, such as PI3K.26
PI3K is an intracellular phosphatidyl inositol kinase, with
serine/threonine (Ser/Thr) kinase activity. A major eﬀector of
PI3K downstream signaling network is Akt, also named as PKB,
a serine/threonine kinase.27 Studies have shown that PI3K–Akt/
PKB pathway could be induced by insulin and act as an indis-
pensable eﬀector.28 Akt/PKB can activate a large number of
downstream molecules, such as translocating glucose trans-
porters (GLUTs), especially by inducing GLUT4 to cell
membrane to increase glucose consumption.29 Therefore, any
defect in the Akt/PKB pathway and downstream molecules may
lead to IR.30 Overall, activation of the PI3K–Akt/PKB pathway is
necessary to promote peripheral glucose uptake and utilization.
Under this background, this study intended to probe the
therapeutic role of CIG against HFD–STZ induced diabetic mice.
Further explored is the underlying mechanism of anti-diabetic
eﬀects conveyed by CIG.
2. Materials and methods
2.1. Chemicals and regents
Crude CF were collected in Foping (Shaanxi, China), as areas in
which the best quality of the herbs can be guaranteed. Raw
materials were authenticated macroscopically and microscopi-
cally according to The Pharmacopoeia of the People's Republic
of China (2015 Edition). Voucher specimens were deposited at
the herbarium at College of Life Science, Shaanxi Normal
University, China (the specimen number is CMQDA
201700011).
Streptozocin (STZ) was purchased from Sigma Chemical Co.
(St Louis, MO, USA). Research Diets D12492 60 kcal% fat were
purchased from Yes Service Biotech (Shanghai, China). Morro-
niside, loganin, sweroside, and cornuside were obtained from
Sigma Chemical Co. (St Louis, MO, USA). All antibodies were
supplied by Cell Signaling Technology (Danvers, MA, USA), and
all other chemicals and reagents were of the highest commer-
cially available grade.
2.2. Extraction of CIG
Corni fructus powder was extracted with 80% methyl alcohol
(1 : 20) for 9 min using an ultrasonic-microwave synergistic
extraction system with a microwave power of 641 W and an
ultrasonic power of 360 W. The pooled extract was ltered and
the solvent was removed by a vacuum rotary evaporator. Dis-
solved the concentrate in distilled water and puried using
D101 macroporous resin elution with 50% ethanol to obtain
CIG. Quantication of CIG was performed by HPLC using
a Shimadzu LC-2010A HPLC system (SHIMADZU, Kyoto, Japan).
CIG was eluted with acetonitrile and 0.2% acetic acid, the ow
rate was 1.0 mL min1, the column temperature was 35 C. The
absorbance wavelength was set at 240 nm for quantication.
2.3. Animals
Seven-week-old male ICR mice (weight 18  2 g) were obtained
from the College of Medicine, Xi'an Jiaotong University (Xi'an,
China). The mice were allowed to freely access to a standard
laboratory rodent food and drinking water. All animals were
maintained in a controlled environment at 25  1 C and 60 
5% relative humidity in a 12 h dark–light cycles and acclima-
tized for one week prior to use. All experiments using mice were
performed in accordance with the National Institute of Health's
Guide for the Care and Use of Laboratory Animals and were
approved by the university's Institutional Animal Care and Use
Committee of Shaanxi Normal University (Xi'an, China).
2.4. Development of T2DM
Before the experiments, all animals were accommodated to the
laboratory environment for one week. T2DM mouse model was
induced according to the previously published method with
some modications.31 Excluding the normal control (NC) group
fed with normal diet (standard laboratory rodent food), other
mice with a high fat diet (HFD) with 60% kcal% fat for 4 weeks.
To induce diabetes, HFD-fed mice were fasted for 12 h before
intraperitoneal injection of STZ solution (in citrate buﬀer, pH
4.2–4.5) at a dose of 40 mg per kg body weight (bw), 5 times
within one week; and the NC group received the citrate buﬀer
alone in parallel. Seventy-two hours aer the last injection,
blood samples were removed from the tail vein of the over-night
fasted mice. We elected mice with FBG >11.1 mmol L1 for
future study, which were recognized as T2DM.
2.5. Experimental groups
Aer the T2DM model was built successfully, the diabetic mice
were randomized into 5 groups of 10 mice each. Grouping and
treatment protocol was listed in Fig. 1. All mice were feeding for
four weeks in a drinking and free drinking water. All mice
weight and fasting blood glucose (FBG) were measured every
week during the experiment. On the 29th day of the experiment,
the mice were fasting for the night and collecting blood samples
via the retro-orbital sinus of mice and separation of serum by
centrifugation and were promptly placed in an environment of
20 C for later research. Following the mice were sacriced via
anaesthesia, tissues of pancreas, liver andmuscle were carefully
separated and washed with icy saline, and each part was xed in
10% formalin (pH 7.4) for biochemical and histological
examinations.
2.6. Oral glucose tolerance test (OGTT)
OGTT was performed in overnight-fasted mice from all groups.
Twenty minutes aer sample administration (NC and DM
groups were oral ingestion with normal saline), the mice were
daily administered with glucose 2.0 g kg1 bw. The samples of
blood were harvested from the tail vein at 0 (before glucose
administration), 30, 60, 120 and 180 min aer glucose admin-
istration using One-Touch glucometer, which was purchased
fromHMD Bio Medical Co. (Taiwan, China). The result of OGTT
30540 | RSC Adv., 2018, 8, 30539–30549 This journal is © The Royal Society of Chemistry 2018
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was represented by an integrated area under the curve (AUC)
calculated by GraphPad Prism version 6.0.
2.7. Biochemical assay
Serum total cholesterol (TC), serum triglycerides (TG), low-
density lipoprotein cholesterol (LDL-C), high-density lipopro-
tein cholesterol (HDL-C), superoxide dismutase (SOD), and
methylene dioxyamphetamine (MDA) were measured using the
marketing diagnostic kit (Nanjing Jiancheng Bioengineering
Institute, China). The serum fasting insulin level (FINS, as
biochemical makers for serum insulin) and inammatory
cytokines (tumor necrosis factor (TNF)-a, interleukin (IL)-6, C-
reactive protein (CRP)) were determined by ELISA assay kits
(Tianjin Anoric Bio-technology CO., Ltd, Tianjin, China). All
measurements were carried out according to the manufac-
turer's protocol of the corresponding kits. The homeostasis
model assessment-insulin sensitivity index (HOMA-IS) and
homeostasis model assessment-insulin resistance index
(HOMA-IR) were calculated following the formulas HOMA-IS ¼
Ln (1/FINS  FBG), HOMA-IR ¼ (FBG  FINS)/22.5, separately.
2.8. H&E staining
Liver and pancreas from diﬀerent groups were rst xed with
10% buﬀered formalin for 24 h, and then buried in paraﬃn.
Final sliced and stained with hematoxylin and eosin (H&E).
Histopathological changes of liver and pancreas were observed
under a light microscope.
2.9. Western-blotting
Aer the mice were sacriced, the protein concentration in
muscle samples was determined by a BCA protein assay kit
(Thermo Scientic, Waltham, MA, USA). And western blot were
analyzed according to the previously method with some modi-
cation.32 Briey, following the tissue was lysed by (radio
immunoprecipitation assay) RIPA buﬀer on ice, the protein
samples were then separated on a 10% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE), transferred to
nitrocellulose membrane (Millipore, MA, USA), and blotted with
primary antibodies at 4 C overnight. The following primary
antibodies were used: INSR, p-INSR, PI3K, p-PI3K, Akt/PKB, p-
Akt/PKB, and GLUT4. The membranes were shaken in a solu-
tion of secondary antibody (peroxidase-conjugated aﬃnipure
goat anti-rabbit or anti-mouse IgG) for 1 h. Infrared uores-
cence were conducted on an Odyssey infrared imaging system
(Li-cor Bioscience, Lincoln, NE, USA). Anti-b-actin was used to
ensure equal loading. Quantication was performed using the
computerized imaging program, Quantity One (Bio-Rad).
2.10. Statistical analysis
Statistical analysis was performed using GraphPad.Prism.v.5.0.
All determinations were done at least in triplicate and all were
averaged. Values were expressed as means  standard devia-
tions (SD). Analysis of variance (ANOVA) was employed to
determine the statistical signicance. And a value of p < 0.05
was considered to be statistically signicant.
3. Results
3.1. HPLC analysis
As shown in Fig. 2 and Table 1, CIG was puried by a multistep
purication procedure including EtOH extraction and D-101
macroporous adsorption resin purication. The contents of
morroniside, loganin, sweroside, and cornuside at concentra-
tions of 1.523%, 0.696%, 0.059%, and 0.169% of the dried fruit,
respectively. The employed HPLC method was validated in
performing the quantitative analysis (Table 2). These results for
method validation suggested that the HPLCmethod established
in our study was reliable for evaluating CIG of Corni fructus.
3.2. Eﬀect of CIG on body weight and organ index
In this study, the concentration of selected CIG extract dose (75,
150, 300 mg kg1) were basing on previous studies,33 where the
extracts researched have similar composition as CIG and show
a hypoglycemic eﬀect. The body weight of each group was
shown in Table 3. The mice in DM group was signicantly
lighter than that of the NC group during the experiment period
(p < 0.05). Diabetic mice that received 4 weeks of CIG were
Fig. 1 Experimental design. ip, intraperitoneal injection; ig, intragastric administration.
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 30539–30549 | 30541
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signicantly increased in body weight compared to that of DM
group (p < 0.05). Aer CIG gavage, the weight of the mice in this
group began to increase, which could be due to the increase of
unused fat-intake; however, these weights started to decrease
aer second week, which might be the result of diabetes
severity.
The liver, kidney and spleen index of group DM was signif-
icantly higher than that of group NC (p < 0.05). However, aer
administration of CIG for 4 weeks, CIG restraining these trends
and the related tissue index returned to normal level (Fig. 3).
3.3. FBG, OGTT and FINS levels
Abnormal glycemic change is a typical characteristic of dia-
betes. As shown in Fig. 4, there was a notable increase in FBG of
DM group when compared to NC group. Compared with the DM
group, the FBG levels in CIG-treated group decreased signi-
cantly aer 4 weeks. Accordingly, OGTT showed that the blood
glucose reached its peak within 30 min and gradually decreased
in the NC group. The CIG-H group exhibited a lower FBG than
DM group at 30 min, which indicates that CIG eﬀective inhi-
bition of the peak of glucose. A lower AUC indicates the higher
eﬃciency of OGTT and our data show that all the CIG groups
had a remarkable low-level of AUC values compared to DM
control. These results indicate that CIG have a positive eﬀect on
blood glucose regulation.
FINS level of the mice in DM group was abnormally lower
than the NC group (p < 0.05) (Table 4), which shown that the
islets were destroyed. However, this trend has been markedly
suppressed by CIG and the FINS level has been raised in CIG-
treated groups (CIG-L increased by 11.11%, CIG-M increased
by 29.20%, CIG-H increased by 50.85%, p < 0.05). In addition,
the study investigated whether or not CIG could exert an
Fig. 2 HPLC chromatogram of (A) reference substances and (B) iridoid glycosides from Corni fructus. Peaks: 1, morroniside; 2, loganin; 3,
sweroside; 4, cornuside.
Table 1 The composition of morroniside, loganin, sweroside and
cornuside in CIG
Peak no. Assigned identity
Retention time
(min)
Contents in
CIG (mg g1)
1 Morroniside 9.71 76.63
2 Loganin 13.62 25.26
3 Sweroside 14.16 2.98
4 Cornuside 26.14 8.45
Table 2 Method validation of morroniside, loganin, sweroside and cornuside by HPLC analysisa
Chemical Calibration curve
Correlation
factor (r2) Linearity (mg mL1)
Precision
RSD (%)
Repeatability
RSD (%) Recovery (%)
Morroniside Y ¼ 3  106x + 505234 0.9999 2.00–18.00 0.23 2.1 98.9
Loganin Y ¼ 2  106x + 332451 0.9999 1.00–8.00 0.05 1.6 99.2
Sweroside Y ¼ 578827x  487447 0.9997 0.10–1.60 0.25 1.7 100.2
Cornuside Y ¼ 456367x  7274.9 0.9996 0.40–2.80 0.19 2.2 98.7
a These samples were subjected to HPLC analysis. The calibration curve was used to calibrate the concentration of various chemical constituents.
The mean values were expressed here, and the standard error of the mean (SEM) values of the six tested chemicals were less than 5% of the mean.
The calibration was repeated 3 times (n ¼ 3).
30542 | RSC Adv., 2018, 8, 30539–30549 This journal is © The Royal Society of Chemistry 2018
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insulin sensitivity and resisting activity in T2DM mice. As
shown in Table 4, in the presence of CIG, the diabetic mice
showed a tendency of enhanced HOMA-IS and HOMA-IR.
These results indicated that CIG ameliorates IR in diabetic
mice.
3.4. Eﬀects of CIG on serum lipid proles of diabetic mice
Diabetes patients oen have disorders in the lipid metabolism.
To test whether CIG would have a protective eﬀect on lipid
metabolism, the eﬀects of CIG on biochemical indicators of
blood lipid in experimental mice are summarized in Fig. 5. TC,
TG and LDL-C levels of DM were signicantly enhanced
compared with that of NC. Such levels decreased aer the
administration of CIG. On the other hand, while HDL-C level of
DM remarkably declined compared with that of NC, such level
of those administered with CIG increased. These results show
that administration of CIG could ameliorates the lipid proles
of diabetic mice especially at the dose of 150 and 300 mg kg1.
3.5. The eﬀects of CIG on inammatory cytokines
As abnormalities in inammation is another characteristic of
diabetes, we also analyzed the levels of the inammatory
cytokines, including IL-6, TNF-a, and CPR in the liver of
experimental mice. Our results showed that under the treat-
ment of CIG at 150 mg kg1 (CIG-M) and 300 mg kg1 (CIG-H),
the expression of IL-6, TNF-a and CRP were signicantly
reduced compared with DM control (Fig. 6). These data indi-
cates that CIG has the ability to improve the inammatory
damage of the liver.
3.6. Eﬀects of CIG on SOD and MDA level in liver
MDA is one of the important products of lipid peroxidation, and
SOD is an important antioxidant enzyme in organism. The
content of MDA and SOD are common used to reect the degree
of lipid peroxidation. As shown in Fig. 7, the level of MDA in DM
group was markedly enhanced compared with NC group. Aer
treat with CIG, the activity of MDA in CIG-M and CIG-H was
obviously lower than that in DM (p < 0.05). Opposite results were
observed regarding in the activities of SOD, which plays
a pivotal role in the oxidation and antioxidant balance.
However, there was no signicant diﬀerence in the SOD and
MDA activity of the CIG-L when compared with that in group
DM.
3.7. CIG improved histopathological damage in the liver and
pancreas
Histopathological analyses revealed that STZ induces severe
injury to the liver and pancreas (Fig. 8). Liver from mice of the
NC group displayed a complete and clear structure, normal and
regular hepatocytes, and uniform cytoplasm. By contrast, DM
Table 3 Eﬀects of CIG on body weight of experimental micea
Group
Body weight (g)
Initial 1 week 2 week 3 week 4 week
NC 31.72  2.26 32.49  2.20 33.18  1.54# 34.22  2.10# 35.18  2.60#
CIG-L 30.50  1.93 30.77  0.63 30.75  1.31 30.6  0.78 30.45  0.54
CIG-M 31.45  0.88 31.80  1.48 30.0  1.62* 30.5  1.95 30.19  2.27
CIG-H 31.33  1.54 31.53  1.36 30.78  2.24* 31.2  2.66# 31.12  2.66#
DM 31.62  2.43 30.23  2.48 29.5  2.28* 28.0  1.97* 27.3  1.78*
a Values are expressed as means  SD of 10 mice in each group, where p < 0.05 denotes statistically signicant diﬀerence with respect to. *, NC
group; #, DM group.
Fig. 3 Eﬀects of CIG on organ weight index of experimental mice. (A) Liver index; (B) spleen index; (C) kidney index; NC, normal control group;
CIG-L, diabetes mice treated with 75 mg kg1 CIG per day; CIG-M, diabetes mice treated with 150 mg kg1 CIG per day; CIG-H, diabetes mice
treated with 300 mg kg1 CIG per day; DM, diabetic mice treated with drinking water. We evaluated p < 0.05 denotes statistically signiﬁcant
diﬀerence with respect to. *, NC group; #, DM group.
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 30539–30549 | 30543
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mice displayed severe damage with a disorder of the hepato-
cytes and the cytoplasm appeared as a vacuole. The CIG treat-
ments signicantly prevented the damage to the liver (Fig. 8A)
It had been generally believed that IR is associated with
insuﬃcient insulin secretion that can induce the damages on
pancreatic b-cells.34 The results of the pancreatic pathology are
shown in Fig. 8B. Group NC had complete pancreatic structure
and a large number of neatly arranged islet beta cells. In
opposite, pancreatic cells in DM group were injured obviously,
focal necrosis and with sparse. However, CIG-treated groups
were alleviating the injury in diﬀerent degrees. All the
histopathological results showed that CIG could delay and treat
the damage of liver and pancreas, and have protective eﬀects on
HFD–STZ induced diabetic mice. Therefore, CIG could be
a potential resource for the prevention and treatment of
diabetes.
3.8. CIG promoted INSR, PI3K, Akt/PKB, and GLUT4
phosphorylation in skeletal muscle of diabetic mice
As one of the major pathogenic mechanism of diabetes, IR
results from a variety of factors.35 IR occurs when binding of
insulin and insulin receptor is compromised or when signal
Fig. 4 Eﬀects of CIG on glycemic modulation of experimental mice. (A) FBG; (B) OGTT; (C) AUC; NC, normal control group; CIG-L, diabetes
mice treated with 75 mg kg1 CIG per day; CIG-M, diabetes mice treated with 150 mg kg1 CIG per day; CIG-H, diabetes mice treated with
300 mg kg1 CIG per day; DM, diabetic mice treated with drinking water. We evaluated p < 0.05 denotes statistically signiﬁcant diﬀerence with
respect to. *, NC group; #, DM group.
Table 4 Eﬀects of CIG on fasting insulin, insulin sensitivity index and insulin resistance index of experimental micea
NC CIG-L CIG-M CIG-H DM
FINS (mIU L1) 11.02  1.23# 7.80  0.89* 9.07  1.15*# 10.59  0.70# 7.02  0.50*
HOMA-IS 4.06  0.21# 5.26  0.10* 5.18  0.11*# 4.94  0.20*# 5.42  0.16*
HOMA-IR 2.87  0.45# 8.05  1.04*# 7.69  0.68*# 6.30  0.80*# 9.10  0.59*
a Data are expressed as the means  standard deviation (SD) for 10 mice in each group, where p < 0.05 denotes statistically signicant diﬀerence
with respect to, *, NC group, #, DM group. HOMA-IR ¼ (FBG  FINS)/22.5. HOMA-IS ¼ Ln (1/FINS  FBG).
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transduction from the insulin receptor is not completed.36
INSR, PI3K, Akt/PKB and GLUT4 are key molecules involved in
glucose uptake and in the signal transduction pathway
triggered by insulin. To study the mechanistic eﬀect of CIG on
IR, western blot analysis of INSR, PI3K, Akt/PKB, and GLUT4
protein levels in skeletal muscle were carried out. Our data
Fig. 5 The eﬀects of CIG on the serum lipid proﬁles of experimental mice. (A) TC; (B) TG; (C) HDL; (D) LDL; NC, normal control group; CIG-L,
diabetes mice treated with 75 mg kg1 CIG per day; CIG-M, diabetes mice treated with 150 mg kg1 CIG per day; CIG-H, diabetes mice treated
with 300 mg kg1 CIG per day; DM, diabetic mice treated with drinking water. We evaluated p < 0.05 denotes statistically signiﬁcant diﬀerence
with respect to. *, NC group; #, DM group.
Fig. 6 The eﬀects of CIG on liver inﬂammatory cytokines of experimental mice. (A) Il-6; (B) TNF-a; (C) CRP. NC, normal control group; CIG-L,
diabetes mice treated with 75 mg kg1 CIG per day; CIG-M, diabetes mice treated with 150 mg kg1 CIG per day; CIG-H, diabetes mice treated
with 300 mg kg1 CIG per day; DM, diabetic mice treated with drinking water. We evaluated p < 0.05 denotes statistically signiﬁcant diﬀerence
with respect to. *, NC group; #, DM group.
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showed that the phosphorylation of these four proteins in
skeletal muscle was signicantly decreased in DM compared
with the group of NC, while CIG-H restored the expression of
INSR, PI3K, Akt/PKB, and GLUT4 (Fig. 9).
4. Discussion
Earlier studies have shown Corni fructus that exhibits immune
regulating function, anti-shock eﬀects and protective eﬀect on
experimental diabetic nephropathy.37,38 Another work has also
raised the possibility that iridoid glycosides might achieve
anti-diabetic eﬀect by inhibiting the phosphorylase of
glycogen,39 in particular, morroniside was suggested to play an
important role in preventing and/or postponing the occur-
rence of diabetic kidney disease. According to the previous
studies, the contents of morroniside, sweroside, loganin and
cornuside in Corni fructus were very rich.40 Thus, we could
assume that CIG not only possesses eﬀects similar to those of
iridoid glycosides, but many also have other functions beyond
the extracted CIGs. In order to develop and utilize of CIG to the
extent of industrial level, the eﬀects of CIG on diabetes were
studied.
Fig. 7 The eﬀects of CIG on liver oxidative stress related factors of experimental mice. (A) MDA; (B) SOD; NC, normal control group; CIG-L,
diabetes mice treated with 75 mg kg1 CIG per day; CIG-M, diabetes mice treated with 150 mg kg1 CIG per day; CIG-H, diabetes mice treated
with 300 mg kg1 CIG per day; DM, diabetic mice treated with drinking water. We evaluated p < 0.05 denotes statistically signiﬁcant diﬀerence
with respect to. *, NC group; #, DM group.
Fig. 8 Histopathological changes in the liver (A) (HE staining 200) and pancreas (B) (HE staining 400).
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In this paper we show that CIG reduces the severity of HFD–
STZ induced diabetes through the modulation of the insulin
signaling pathway. First of all, ICR mice became diabetes mel-
litus induce by HFD and multiple low-dose STZ injections.41
Aer the diabetes model was established, CIG gavage was used
at the doses of 75 (low dose), 150 (medium dose) and 300 (high
dose) mg per kg per day in the experiment. HFD/STZ-induced
diabetic mice administrated with CIG daily were investigated
for the eﬀects on various parameters, including body weight,
FBG, lipid level, FINS, antioxidant ability, inammatory cyto-
kines and other parameters involving liver, pancreas and skel-
etal muscle. As shown in Table 3, while body weights of the CIG-
treated HFD/STZ-induced diabetic mice increases, the increase
of FBG levels was signicantly suppressed (Fig. 4A). This result
suggested that CIG may delay dietary carbohydrates' absorp-
tion, resulting the blood glucose level decrease.
Because impaired OGTT is an important criterion for dia-
betes. The OGTT was thus conducted and the results were
shown in Fig. 4B. Reports have previously demonstrated the
benecial action of Corni fructus on diet-induced IR and glucose
intolerance.42 In this research, OGTT indicated that the AUC of
glucose tolerance in CIG was lower appreciably than that in the
DM (p < 0.05) (Fig. 4B and C), showing that CIG has an eﬀective
improvement of glucose tolerance in diabetic mice. IR is the
main symptom of T2DM, which is related to the injury of
insulin secretion and hyperglycemia caused by STZ injection. In
this research, the insulin levels in group CIG were signicantly
higher than those in group DM, suggesting that CIG stimulates
insulin secretion in islets of diabetic mice. IR was dened as
HOMA-IR > 2.6,43–45 a higher level of HOMA-IR and lower HOMA-
IS showed the dysfunction of b-cell in DM group mice (Table 4).
However, the HOMA-IR and HOMA-IS levels of all CIG mice
were signicantly reduced and increased, demonstrating that
CIG could ameliorate b-cell function and IR.
Moreover, cinnamon polyphenols longstanding IR will also
interfere with the metabolism of glucose and lipid, leading to
a further rise in glycolipid levels.46 Hyperlipidemia and dysli-
pidemia are closely related to diabetes, which is a metabolic
disorder caused by diabetes.47 In this research, CIG intake
obviously depressed TC, TG levels and increased HDL levels in
the mice of DM group (Fig. 5). Elevated levels of TC and TG are
associated with high diabetes risk, while increased HDL levels
can alleviate diabetes.46
As we all know, oxidative stress plays a key role in the
pathogenesis of diabetes and his complications.48,49 And some
cytokines like IL-6, TNF-a and CRP, also have been related to the
risk of developing T2DM and cardiovascular diseases that are
strongly associated with IR and body fat amount.50 Oxidative
stress and inammation can interact, IL-6 and TNF-a can
stimulate the production of reactive oxygen species, which
could activate a variety of signal transduction mechanisms in
the cell, and leads to IR eventually.51 Consistently, DM mice
herein had markedly enhanced lipid peroxidation product
MDA, and reduced activities of antioxidant enzymes SOD.52,53 In
the present study, we found that CIG could inhibit the expres-
sion of IL-6, TNF-a, CRP and MDA, and increase the SOD levels
in the liver. These results suggest that CIG blocks the patho-
genesis of diabetes by inhibiting the production of pro-
inammatory cytokines.
Aside from the IR of liver, the IR of muscle and adipose are
the two other main aﬀected organs in diabetes. Skeletal muscle
plays an important role in glucose and lipid homeostasis via
regulation of the insulin signaling pathway.54 To clarify the
mechanism of CIG in treating diabetes, we detected the mRNA
and protein expression of the main targets of the insulin
transduction pathway in skeletal muscle. Insulin exerts its
action through the activation of PI3K by the INSR. INSR is
activated by tyrosine phosphorylation and is the central
Fig. 9 Protein status and gene expressions of key enzymes of glucose metabolism in skeletal muscle. NC, normal control group; CIG-H,
diabetes mice treated with 300 mg kg1 CIG per day; DM, diabetic mice treated with boiled water. We evaluated p < 0.05 denotes statistically
signiﬁcant diﬀerence with respect to. *, NC group; #, DM group.
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mediator in the insulin response upstream of PI3K.55 Many
studies have shown that Akt/PKB plays an important role in
insulin action, including increased glucose uptake and GLUT4
translocation.56 Therefore, increase of Akt/PKB activity was
considered to be closely connected to the increase of glucose
uptakes and insulin signaling cascade activation, and Akt/PKB
is the primary target of PI3K-generated signals.28 Akt/PKB acti-
vates AS160 (Akt substrate, 160 kDa), which promotes the
translocation of GLUT4 and absorption of glucose in muscle
cells. More recently, evidence showed that increasing the
secretion of GLUT4 in adipose or skeletal muscles reverse b-cell
from necrosis.57 Polysaccharides from Ganoderma lucidum were
also shown to be involved in the modulation of GLUT4 expres-
sion in the treatment of diabetic mice.58 Therefore, PI3K–Akt/
PKB signaling pathway plays a key part in metabolic eﬀect.59
The lower expression of PI3K, Akt/PKB and GLUT4 expression
levels in STZ–HFD induced diabetic mice compared to control
mice suggested that glucose uptake via GLUT4 into cells
through PI3K–Akt/PKB signal pathway was inhibited. In our
ndings, CIG could increase the protein expression of INSR,
PI3K, Akt/PKB, and GLUT4 in skeletal muscle, demonstrating
that the hypoglycemic activity of CIG is mediated by the PI3K–
Akt/PKB signaling pathway, which could improve IR.
5. Conclusion
In conclusion, we demonstrate that CIG has a hypoglycemic,
hypolipidemic and antioxidant eﬀects in diabetes. The possible
mechanism of this eﬀect may be related to the activation of the
PI3K–Akt/PKB signaling pathway. CIG could be developed as
a potential therapeutic treatment for diabetes.
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